Transcriptome Subtraction Pinpoints Unknown Viruses in Human Serum
By LabMedica International staff writers Posted on 02 Jul 2013 |
An approach based on subtracting viral DNA and RNA from that normally present in human serum and then comparing the results to databases of known viral genomes enables screening patients for the presence of unknown viruses.
Investigators at St. Louis University (MO, USA) recently described the use of the next-generation sequencing approach called transcriptome subtraction to look for unknown viral sequences in samples of serum. Transcriptome subtraction requires ultradeep sequencing to establish which DNA and RNA belong to the human genome and separate this material from extraneous viral nucleic acids.
Depth in DNA sequencing refers to the number of times a nucleotide is read during the sequencing process. Deep sequencing indicates that the coverage, or depth, of the process is many times larger than the length of the sequence under study. The term "deep" has been used for a wide range of depths (at least seven times), and the newer term "ultradeep" has appeared in the scientific literature to refer to even higher coverage (at least 100 times). Even though the sequencing accuracy for each individual nucleotide is very high, the very large number of nucleotides in the genome means that if an individual genome is only sequenced once, there will be a significant number of sequencing errors. Furthermore, rare single-nucleotide polymorphisms (SNPs) are common. Hence to distinguish between sequencing errors and true SNPs, it is necessary to increase the sequencing accuracy even further by sequencing individual genomes a large number of times.
After the human genome was identified and removed from the equation, the investigators used data from well-curated databases and advanced bioinformatic tools to eliminate DNA and RNA from all known viruses. Any nucleic acids remaining belonged to unknown viruses.
“We have discovered a technology that allows us to detect new viruses,” said contributing author Dr. Adrian Di Bisceglie, professor of internal medicine at Saint Louis University. “We isolate DNA and RNA, amplify the amount of genetic material present in the blood, do ultradeep sequencing, and use an algorithm to search for matches for every known piece of genetic code, both human and for microbes. Just as the human microbiome project is chronicling the bacteria that live and coexist in every person, we also are studying the human virome to know more about the viruses that live in all of us—we believe not all are harmful and some may even be beneficial.”
The study was published in the June 11, 2013, online edition of the journal Biochemical and Biophysical Research Communications.
Related Links:
St. Louis University
Investigators at St. Louis University (MO, USA) recently described the use of the next-generation sequencing approach called transcriptome subtraction to look for unknown viral sequences in samples of serum. Transcriptome subtraction requires ultradeep sequencing to establish which DNA and RNA belong to the human genome and separate this material from extraneous viral nucleic acids.
Depth in DNA sequencing refers to the number of times a nucleotide is read during the sequencing process. Deep sequencing indicates that the coverage, or depth, of the process is many times larger than the length of the sequence under study. The term "deep" has been used for a wide range of depths (at least seven times), and the newer term "ultradeep" has appeared in the scientific literature to refer to even higher coverage (at least 100 times). Even though the sequencing accuracy for each individual nucleotide is very high, the very large number of nucleotides in the genome means that if an individual genome is only sequenced once, there will be a significant number of sequencing errors. Furthermore, rare single-nucleotide polymorphisms (SNPs) are common. Hence to distinguish between sequencing errors and true SNPs, it is necessary to increase the sequencing accuracy even further by sequencing individual genomes a large number of times.
After the human genome was identified and removed from the equation, the investigators used data from well-curated databases and advanced bioinformatic tools to eliminate DNA and RNA from all known viruses. Any nucleic acids remaining belonged to unknown viruses.
“We have discovered a technology that allows us to detect new viruses,” said contributing author Dr. Adrian Di Bisceglie, professor of internal medicine at Saint Louis University. “We isolate DNA and RNA, amplify the amount of genetic material present in the blood, do ultradeep sequencing, and use an algorithm to search for matches for every known piece of genetic code, both human and for microbes. Just as the human microbiome project is chronicling the bacteria that live and coexist in every person, we also are studying the human virome to know more about the viruses that live in all of us—we believe not all are harmful and some may even be beneficial.”
The study was published in the June 11, 2013, online edition of the journal Biochemical and Biophysical Research Communications.
Related Links:
St. Louis University
Latest Technology News
- Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
- Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
- Smartphones Could Diagnose Diseases Using Infrared Scans
- Novel Sensor Technology to Enable Early Diagnoses of Metabolic and Cardiovascular Disorders
- 3D Printing Breakthrough Enables Large Scale Development of Tiny Microfluidic Devices
- POC Paper-Based Sensor Platform to Transform Cardiac Diagnostics
- Study Explores Impact of POC Testing on Future of Diagnostics
- Low-Cost, Fast Response Sensor Enables Early and Accurate Detection of Lung Cancer
- Nanotechnology For Cervical Cancer Diagnosis Could Replace Invasive Pap Smears
- Lab-On-Chip Platform to Expedite Cancer Diagnoses
- Biosensing Platform Simultaneously Detects Vitamin C and SARS-CoV-2
- New Lens Method Analyzes Tears for Early Disease Detection
- FET-Based Sensors Pave Way for Portable Diagnostic Devices Capable of Detecting Multiple Diseases
- Paper-Based Biosensor System to Detect Glucose Using Sweat Could Revolutionize Diabetes Management
- First AI-Powered Blood Test Identifies Patients in Earliest Stage of Breast Cancer
- Optical Biosensor Rapidly Detects Monkeypox Virus at Point of Care
Channels
Clinical Chemistry
view channel
Carbon Nanotubes Help Build Highly Accurate Sensors for Continuous Health Monitoring
Current sensors can measure various health indicators, such as blood glucose levels, in the body. However, there is a need to develop more accurate and sensitive sensor materials that can detect lower... Read more
Paper-Based Device Boosts HIV Test Accuracy from Dried Blood Samples
In regions where access to clinics for routine blood tests presents financial and logistical obstacles, HIV patients are increasingly able to collect and send a drop of blood using paper-based devices... Read moreMolecular Diagnostics
view channel
Novel Cell-Based Assay Provides Sensitive and Specific Autoantibody Detection in Demyelination
Anti-myelin-associated glycoprotein (MAG) antibodies serve as markers for an autoimmune demyelinating disorder that affects the peripheral nervous system, leading to sensory impairment. Anti-MAG-IgM antibodies... Read more
Novel Point-of-Care Technology Delivers Accurate HIV Results in Minutes
HIV diagnostic methods have traditionally relied on detecting HIV-specific antibodies, which typically appear weeks after infection. This delayed detection has hindered early diagnosis, complicating patient... Read moreHematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read moreImmunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read moreMicrobiology
view channel
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read moreInnovative ID/AST System to Help Diagnose Infectious Diseases and Combat AMR
Each year, 11 million people across the world die of sepsis out of which 1.3 million deaths are due to antibiotic-resistant bacteria. The burden of antimicrobial resistance (AMR) continues to weigh heavily,... Read more
Gastrointestinal Panel Delivers Rapid Detection of Five Common Bacterial Pathogens for Outpatient Use
Acute infectious gastroenteritis results in approximately 179 million cases each year in the United States, leading to a significant number of outpatient visits and hospitalizations. To address this, a... Read morePathology
view channel
AI Model Effectively Predicts Patient Outcomes in Common Lung Cancer Type
Lung adenocarcinoma, the most common form of non-small cell lung cancer (NSCLC), typically adopts one of six distinct growth patterns, often combining multiple patterns within a single tumor.... Read more
AI Model Predicts Patient Response to Bladder Cancer Treatment
Each year in the United States, around 81,000 new cases of bladder cancer are diagnosed, leading to approximately 17,000 deaths annually. Muscle-invasive bladder cancer (MIBC) is a severe form of bladder... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more